|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1995-2-22
|
|
pubmed:abstractText |
The identification of antigenic peptides presented on the tumor cell surface by HLA class I molecules and recognized by tumor-specific cytotoxic T lymphocytes may lead to a peptide vaccine capable of inducing protective cellular immunity. We demonstrate that both HLA-A2-restricted breast and ovarian tumor-specific cytotoxic T lymphocytes recognize shared antigenic peptides. At least one of these peptides is derived from the oncogene product of HER2/neu, which is overexpressed in 30-40% of all breast and ovarian cancers. T cells sensitized against this nine-amino acid sequence demonstrate significant recognition of HLA-A2+, HER2/neu+ tumors. Since 50% of the tumor-cell population is HLA-A2+ and many different tumors express HER2/neu, this peptide may be widely recognized and have many clinical applications.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-1546329,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-1709722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-1721637,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-1840703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-1967224,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-2469442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-2470152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-2788708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-2885917,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-2999974,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-3003577,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-3093588,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-3262416,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-7505195,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-7513441,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-7690811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-7691418,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-7912166,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8104103,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8133050,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8170938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8215637,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8228240,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8342128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8409397,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8459226,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7831305-8469924
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
17
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
432-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:7831305-Antigens, Neoplasm,
pubmed-meshheading:7831305-Base Sequence,
pubmed-meshheading:7831305-Breast Neoplasms,
pubmed-meshheading:7831305-Cross Reactions,
pubmed-meshheading:7831305-Cytotoxicity, Immunologic,
pubmed-meshheading:7831305-Female,
pubmed-meshheading:7831305-HLA-A2 Antigen,
pubmed-meshheading:7831305-Humans,
pubmed-meshheading:7831305-Immunization,
pubmed-meshheading:7831305-Lymphocytes, Tumor-Infiltrating,
pubmed-meshheading:7831305-Molecular Sequence Data,
pubmed-meshheading:7831305-Ovarian Neoplasms,
pubmed-meshheading:7831305-Peptide Fragments,
pubmed-meshheading:7831305-Receptor, erbB-2,
pubmed-meshheading:7831305-T-Lymphocytes
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.
|
|
pubmed:affiliation |
Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
